-
11.发明授权Soluble extracellular fragment of the human IFN-beta 2/IL-6 receptor, its preparation and pharmaceutical compositions containing it 失效Löslisches人类IFN金属-β2/ IL-6受体，其制备的细胞外片段和含有药物混合物该片段
公开(公告)号：EP0413908B1
公开(公告)日：1996-09-25
申请号：EP90110487.7
申请日：1990-06-01
Inventor： Novick, Daniela , Chen, Louis , Engelmann, Hartmut , Revel, Michel , Rubinstein, Menachem , Wallach, David
CPC classification number: C07K14/715 , A61K38/215 , C07K14/7155 , Y10S530/834 , A61K2300/00
-
12.发明授权Human interferon beta2A, vectors containing genes coding for said interferon, cell lines producing same 失效人间干扰素BETA2A，含有干扰素基因编码的载体，生产同源物的细胞系
公开(公告)号：EP0220574B1
公开(公告)日：1993-07-07
申请号：EP86114049.9
申请日：1986-10-10
Inventor： Revel, Michel , Zilberstein, Asher
CPC classification number: C07K14/565 , A61K38/215 , C07K14/5412
-
公开(公告)号：EP0159714B1
公开(公告)日：1992-07-15
申请号：EP85105058.3
申请日：1985-04-25
Inventor： Revel, Michel , Rubinstein, Menachem , Mory, Yves
-
Patent Agency Ranking14.发明公开Human IFN-beta2/IL-6, its purification and uses 失效Menschliches IFN-β2/ IL-6，dessen Reinigung und Verwendungen。
公开(公告)号：EP0326120A2
公开(公告)日：1989-08-02
申请号：EP89101295.7
申请日：1989-01-25
Inventor： Revel, Michel , Rubinstein, Menachem , Mory, Yves , Chen, Louise , Novick, Daniela , Michalevicz, Rita
CPC classification number: C07K16/248 , A61K38/00 , C07K14/31 , C07K14/5412 , C07K2317/77 , C07K2319/705 , C07K2319/75
Abstract: Monoclonal antibodies to IFN-β2/IL-6 and hybridomas producing them and production and purification of glycosylated and unglycosylated IFN-β2/ IL-6 are disclosed. The protein is useful in the treatment of breast cancer, leukemia, infectious diseases and bone marrow progenitor cell disorders.
Abstract translation: 公开了IFN-β2/ IL-6的单克隆抗体和产生它们的杂交瘤以及糖基化和未糖基化的IFN-β2/ IL-6的产生和纯化。 该蛋白质可用于治疗乳腺癌，白血病，感染性疾病和骨髓祖细胞疾病。
-
公开(公告)号：EP0159714A3
公开(公告)日：1988-03-30
申请号：EP85105058
申请日：1985-04-25
Inventor： Revel, Michel , Rubinstein, Menachem , Mory, Yves
Abstract: Interferon y is produced in highly purified form (activity exceeding 10 8 units/ml-day) by CHO cells cotransformed by a first plasmid bearing the genomic human interferon gene under the control of the SV40 early promoter, and a second plasmid bearing a DHFR gene under similar control. Methotrexate selection yielded a clone which was a particularly efficient producer. Production of interferon y may also be facilitated by a Harvey sarcoma virus enhancer sequence.
-
16.发明公开Antiviral pharmaceutical compositions containing hypericin or pseudohypericin 失效Antivirale pharmazeutische Zusammensetzungen enthaltende Hypericine oder Pseudohypericine。
公开(公告)号：EP0256452A2
公开(公告)日：1988-02-24
申请号：EP87111467.4
申请日：1987-08-07
Inventor： Lavie, David , Revel, Michel , Rotman, Dalia , Vande Velde, Vincent
IPC: A61K31/12
CPC classification number: A61K31/12
Abstract: Described is the use of hypericin or pseudohypericin as active therapeutic substances in the treatment of, and alleviation of symptoms of various diseases caused by viruses such as vesicular stomatitis, influenza, herpes simplex, HSV-1 and HSV-2. The mode of activity seems to be by inhibition of RNA synthesis and interfering with virus replication. Pharmaceutical compositions can be applied by a variety of routes. Topical applications have proved to be effective against a variety of viral afflictions.
Abstract translation: 描述了金丝桃素或假倍他辛霉素作为活性治疗物质在治疗和缓解由诸如水泡性口炎，流感，单纯疱疹，HSV-1和HSV-2等病毒引起的各种疾病的症状的用途。 活动模式似乎是通过抑制RNA合成和干扰病毒复制。 药物组合物可以通过各种途径施用。 已证明局部应用对各种病毒性疾病有效。
-
17.发明公开Human interferon beta2A, vectors containing genes coding for said interferon, cell lines producing same 失效人干扰素beta2A; 含有编码用于所述干扰素基因的载体; 细胞系生产这种及使用所述干扰素作为药物。
公开(公告)号：EP0220574A1
公开(公告)日：1987-05-06
申请号：EP86114049.9
申请日：1986-10-10
Inventor： Revel, Michel , Zilberstein, Asher
CPC classification number: C07K14/565 , A61K38/215 , C07K14/5412
Abstract: Human interferon-beta 2A and interferon-beta 2B are produced in purified form by recombinant DNA techniques. Two separate human genes have been identified which code for the production of IFN-β 2A and IFN-β 2B , respectively. The sequence of IFN-β 2A cDNA is established. These genes and cDNA have been cloned into mammalian cells with an SV40 early promoter sequence and such genomic clones are capable of producing IFN-β 2A and IFN-β 2B . The antiviral activity of such recombinant IFN-β 2A and IFN-β 2B is demonstrated as well as other biological activity identifying them as human interferons. It has been shown that IFN-β₂ secretion is induced in human cells by growth-stimulatory cytokines.
Abstract translation: 重组人干扰素beta2A和干扰素beta2B以纯化的形式是新的。 所以新的用于合成的cDNA，其编码，重组载体contg。 中的cDNA和细胞系contg。 向量。
-
公开(公告)号：EP0159714A2
公开(公告)日：1985-10-30
申请号：EP85105058.3
申请日：1985-04-25
Inventor： Revel, Michel , Rubinstein, Menachem , Mory, Yves
Abstract: Interferon y is produced in highly purified form (activity exceeding 10 8 units/ml-day) by CHO cells cotransformed by a first plasmid bearing the genomic human interferon gene under the control of the SV40 early promoter, and a second plasmid bearing a DHFR gene under similar control. Methotrexate selection yielded a clone which was a particularly efficient producer. Production of interferon y may also be facilitated by a Harvey sarcoma virus enhancer sequence.
-
-
-
-
-
-
-
Search Results
18
records
(took 0.034 seconds)
